Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,382 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

Regulatory T cells, tumour immunity and immunotherapy

Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,075 · see citing works

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works

Inhibitory B7-family molecules in the tumour microenvironment

Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608 · see citing works

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589 · see citing works

Whole-genome landscapes of major melanoma subtypes

Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,466 · see citing works

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018 · see citing works

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 892 · see citing works

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · see citing works

Incidence of noncutaneous melanomas in the U.S.

McLaughlin, C. C., Wu, X., Jemal, A., Martin, H. J., Roche, L. M., & Chen, V. W. (2005) · Cancer · doi:10.1002/cncr.20866 · Cited by 741 · see citing works

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

Blank, C. U., & Mackensen, A. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0272-1 · Cited by 502 · see citing works

The melanoma revolution: From UV carcinogenesis to a new era in therapeutics

Lo, J. A., & Fisher, D. E. (2014) · Science · doi:10.1126/science.1253735 · Cited by 426 · see citing works

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

Chi, Z., Li, S., Sheng, X., Si, L., Cui, C., Han, M., & Guo, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-85 · Cited by 386 · see citing works

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338 · see citing works

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy

Tsushima, F., Yao, S., Shin, T., Flies, A. S., Flies, S. J., Xu, H., Tamada, K., Pardoll, D. M., & Chen, L. (2007) · Blood · doi:10.1182/blood-2006-11-060087 · Cited by 237 · see citing works

The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis

Furney, S. J., Turajlic, S., Stamp, G., Thomas, J., Hayes, A. J., Strauß, D., Gavrielides, M., Xing, W., Gore, M. E., Larkin, J., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12279 · Cited by 141 · see citing works

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Kong, Y., Sheng, X., Wu, X., Yan, J., Ma, M., Yu, J., Si, L., Chi, Z., Cui, C., Dai, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0070 · Cited by 100 · see citing works

Diagnosis and Management of Acral Lentiginous Melanoma

Nakamura, Y., & Fujisawa, Y. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0560-y · Cited by 67 · see citing works

Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody

Fu, J., Wang, F., Dong, L., Zhang, J., Deng, C.-L., Wang, X., Xie, X.-Y., Zhang, J., Deng, R., Zhang, L., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.161 · Cited by 54 · see citing works

Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry

Cho, J., Ahn, S., Yoo, K. H., Kim, H. J., Choi, S., Jang, K., & Lee, J. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0373-4 · Cited by 40 · see citing works

Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma.

Cui, C., Tang, B., & Guo, J. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.07.02 · Cited by 16 · see citing works

EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations

Navazio, A. S., Rizzolo, P., Silvestri, V., Valentini, V., Zelli, V., Zanna, I., Masala, G., Bianchi, S., Tommasi, S., Palli, D., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3976-8 · Cited by 8 · see citing works

Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity

Karim, L. A., Kallakury, B., Chahine, J. J., Sheehan, C. E., & Ross, J. S. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000609 · Cited by 3 · see citing works

A model based adjustment for tumor mutational burden across different tumor types

Wang, M., Shi, W. W., Zhang, P., Zhao, S., Cao, J., Chen, M. W., Shou, T., Hu, J., Tang, X., & Song, T. Q. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx509.004 · Cited by 2 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Lü, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Neotorch Investigators, Fang, W., Xing, W., Chen, Q., Yang, L., et al. (2024) · JAMA · doi:10.1001/jama.2023.24735 · Cited by 405 · see citing works

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 403 · see citing works

T Cell Dysfunction in Cancer Immunity and Immunotherapy

Xia, A., Zhang, Y., Jiang, X., Yin, T., & Lu, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 338 · see citing works

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Mai, H., Chen, Q., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y., Jin, F., Xu, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.20181 · Cited by 296 · see citing works

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Pan, C.-X., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00862-w · Cited by 245 · see citing works

Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils

Shang, A., Wang, W., Gu, C., Chen, C., Zeng, B., Yang, Y., Ji, P., Sun, J., Wu, J., Lu, W., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1394-6 · Cited by 185 · see citing works

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00210 · Cited by 175 · see citing works

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3922 · Cited by 168 · see citing works

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Shi, G., Huang, X., Wu, D., Sun, H., Liang, F., Ji, Y., Chen, Y., Yang, G., Lu, J., Meng, X., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01317-7 · Cited by 165 · see citing works

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163 · see citing works

Toripalimab: First Global Approval

Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01076-2 · Cited by 159 · see citing works

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Li, J., Deng, Y., Zhang, W., Zhou, A., Guo, W., Yang, J., Yuan, Y., Zhu, L., Qin, S., Xiang, S., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01095-1 · Cited by 151 · see citing works

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis

Wu, Y., Xu, J., Du, C., Wu, Y., Xia, D., Lv, W., & Hu, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01161 · Cited by 138 · see citing works

Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Lu, M. S., Zhang, P., Zhang, Y., Li, Z., Gong, J., Li, J., Li, J., Li, Y., Zhang, X., Lü, Z., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4000 · Cited by 111 · see citing works

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, R., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 113 · see citing works

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

Shi, Y., Lei, Y., Liu, L., Zhang, S., Wang, W., Zhao, J., Zhao, S., Dong, X., Yao, M., Wang, K., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3649 · Cited by 106 · see citing works

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

Zhang, L., Hao, B., Geng, Z., & Geng, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730666 · Cited by 103 · see citing works

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100 · see citing works

Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3168 · Cited by 98 · see citing works

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 94 · see citing works

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

Yan, X. Q., Ye, M., Zou, Q., Chen, P., He, Z. S., Wu, B., He, D., He, C. H., Xue, X., Ji, Z., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3108 · Cited by 91 · see citing works

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients

Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 82 · see citing works

Future Challenges in Cancer Resistance to Immunotherapy

van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 74 · see citing works

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

Sheng, X., Chen, H., Hu, B., Yao, X., Liu, Z., Yao, X., Guo, H., Hu, Y., Ji, Z., Luo, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2210 · Cited by 70 · see citing works

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth

Qin, L., Zhao, R., Chen, D., Wei, X., Wu, Q., Long, Y., Jiang, Z., Li, Y., Wu, H., Zhang, X., et al. (2020) · Biomarker Research · doi:10.1186/s40364-020-00198-0 · Cited by 68 · see citing works

Translational pathology, genomics and the development of systemic therapies for acral melanoma

Chen, Y. A., Teer, J. K., Eroglu, Z., Wu, J.-Y., Koomen, J. M., Karreth, F. A., Messina, J. L., & Smalley, K. S. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.017 · Cited by 60 · see citing works

Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer

Huang, H., Nie, C., Liu, X., Song, B., Yue, J., Xu, J.-X., He, J., Li, K., Feng, Y., Wan, T., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157726 · Cited by 59 · see citing works

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

Wei, X., Ren, C., Wang, F., Zhang, Y., Zhao, H., Zou, B., Wang, Z., Qiu, M., Zhang, D., Luo, H., et al. (2020) · 癌症：英文版 · doi:10.1002/cac2.12068 · Cited by 56 · see citing works

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore

Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 56 · see citing works

Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective

Danielpour, D. (2024) · Pharmaceuticals · doi:10.3390/ph17040533 · Cited by 52 · see citing works

EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer

Zhou, J.-T., Liu, J.-H., Song, T., Ma, B., Amidula, N., & Bai, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s260915 · Cited by 50 · see citing works

Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.

Wang, S., Shi, H., Liu, T., Li, M., Zhou, S., Qiu, X., Wang, Z., Hu, W.-Y., Guo, W., Chen, X.-Q., et al. (2019) · Hepatobiliary surgery and nutrition · doi:10.21037/hbsn.2019.09.17 · Cited by 42 · see citing works

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors

Moeckel, C. M., Bakhl, K., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076710 · Cited by 48 · see citing works

Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer

Wang, Z., Ying, J., Xu, J., Yuan, P., Duan, J., Bai, H., Guo, C., Li, L., Yang, Z., Wan, R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13770 · Cited by 48 · see citing works

The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis

Cao, J., Yang, X., Chen, S., Wang, J., Fan, X., Fu, S., & Yang, L. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101375 · Cited by 46 · see citing works

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population

Li, L., Li, G., Rao, B., Dong, A.-H., Liang, W., Zhu, J., Qin, M.-P., Huang, W., Lu, J., Li, Z.-F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72649-5 · Cited by 46 · see citing works

Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application

Li, A., & Fang, J. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230025 · Cited by 42 · see citing works

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109638 · Cited by 42 · see citing works

Mechanisms of Resistance to Checkpoint Blockade Therapy

Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 37 · see citing works

Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

Chen, C., Liu, S., Jiang, X., Huang, L., Chen, F., Wei, X., Guo, H., Shao, Y. W., Li, Y., & Li, W. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00215-4 · Cited by 37 · see citing works

Butyrate facilitates immune clearance of colorectal cancer cells by suppressing STAT1-mediated PD-L1 expression

Zhang, Y., Tao, Y., Gu, Y., & Ma, Q. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100303 · Cited by 36 · see citing works

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

Yang, J., He, X., Lv, Q., Jing, J., & Shi, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00726 · Cited by 36 · see citing works

Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice

Huang, H., Zhu, H., Xie, Q., Tian, X., Yang, X., Feng, F., Jiang, Q., Sheng, X., & Yang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.004 · Cited by 33 · see citing works

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Jiang, J., Ding, Y., Wu, M., Chen, Y., Lyu, X., Lü, J., Wang, H., & Teng, L. (2020) · Cancer Medicine · doi:10.1002/cam4.3481 · Cited by 33 · see citing works

Toripalimab for the treatment of melanoma

Tang, B., Chi, Z., & Guo, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1762561 · Cited by 30 · see citing works

Imaging diagnosis and efficacy monitoring by [ 89 Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies

He, H., Qi, X., Fu, H., Xu, J., Zheng, Q., Chen, L., Zhang, Y., Hua, H., Xu, W., Xu, Z., et al. (2023) · Theranostics · doi:10.7150/thno.87243 · Cited by 30 · see citing works

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review

Zheng, Q., Li, J., Zhang, H., Wang, Y., & Zhang, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602705 · Cited by 28 · see citing works

Efficacy and safety of PD ‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study

Yao, J., Zhu, X., Wu, Z., Wei, Q., Cai, Y., Zheng, Y., Hu, X., Hu, H., Zhang, X., Pan, H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4747 · Cited by 27 · see citing works

A Rare EGFR–SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib

Li, Y., Zhang, H., Chen, X., Yang, X., Ye, Y., Bekaii‐Saab, T., Zheng, Y., & Zhang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0405 · Cited by 25 · see citing works

Advanced Acral Melanoma Therapies: Current Status and Future Directions

Zhang, Y., Lan, S., & Wu, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01007-6 · Cited by 26 · see citing works

Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation

Zhang, W., Shi, J., Li, R., Han, Z., Li, L., Li, G., Yang, B., Yin, Q., Wang, Y., Ke, Y., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0498 · Cited by 24 · see citing works

Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma

Zhao, L., Fu, X., Han, X., Yu, Y., Ye, Y., & Gao, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01774-6 · Cited by 24 · see citing works

Toripalimab in advanced biliary tract cancer

Li, W., Wang, Y., Yu, Y., Li, Q., Wang, Y., Zhang, C., Xu, X., Guo, X., Dong, Y., Cui, Y., et al. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100255 · Cited by 24 · see citing works

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives

Zhao, Y., Liu, L., & Weng, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.714483 · Cited by 23 · see citing works

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

Jahangir, M., Yazdani, O., Kahrizi, M. S., Soltanzadeh, S., Javididashtbayaz, H., Mivefroshan, A., Ilkhani, S., & Esbati, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02816-3 · Cited by 22 · see citing works

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

Jiang, M., Liu, M., Liu, G., Ma, J., Zhang, L., & Wang, S. (2023) · mAbs · doi:10.1080/19420862.2023.2236740 · Cited by 23 · see citing works

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies

Ding, L., Dong, H., Zhou, T. R., Wang, Y. H., Yan, T., Li, J. C., Wang, Z. Y., Liang, C., & Liang, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4190 · Cited by 22 · see citing works

Immunotherapy for gastric cancer: Advances and challenges

Zhang, P., Zhang, C., Li, X., Chang, C., Gan, C., Ye, T., & Cao, D. (2024) · MedComm – Oncology · doi:10.1002/mog2.92 · Cited by 21 · see citing works

Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy

Lv, P., Chen, X., Fu, S., Ren, E., Liu, C., Liu, X., Jiang, L., Zeng, Y., Wang, X., & Liu, G. (2021) · Biomaterials Science · doi:10.1039/d1bm00928a · Cited by 21 · see citing works

Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab

Wang, S., Zhu, H., Ding, J., Wang, F., Meng, X., Ding, L., Zhang, Y., Li, N., Yao, S., Sheng, X., et al. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003520 · Cited by 20 · see citing works

Manganese in health and disease

Wang, Y., Li, J., Jing, Z., Wu, Y., Liu, J., & Han, S. (2025) · Nutrition Research Reviews · doi:10.1017/s0954422425100139 · Cited by 18 · see citing works

Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis

Wan, L., Wang, Z., Xue, J., Yang, H., & Zhu, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1131 · Cited by 17 · see citing works

The Landscape of Nanovectors for Modulation in Cancer Immunotherapy

Volovăț, S. R., Lupaşcu-Ursulescu, C. V., Gheorghe, L., Volovat, C. D., Boboc, D., Scripcariu, D. V., Amurariti, F., Ştefănescu, C., Stolniceanu, C. R., Agop, M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020397 · Cited by 18 · see citing works

Unveiling the Role of Tumor-Infiltrating T Cells and Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review

Chen, X., Liu, X., & Du, S. (2023) · Cancers · doi:10.3390/cancers15205046 · Cited by 18 · see citing works

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients

Guo, G. F., Li, G., Liu, Y., Li, H., Guo, Q., Liu, J., Yang, X., Shou, T., & Shi, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621422 · Cited by 17 · see citing works

Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers

Niknafs, N., Najjar, M., Dennehy, C., Stouras, I., & Anagnostou, V. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0824 · Cited by 15 · see citing works

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

Tang, B., Chen, Y., Jiang, Y. J., Fang, M., Gao, Q., Ren, X., Li, Y., Huang, G., Chen, J., Zhang, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009662 · Cited by 15 · see citing works

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma

Lin, J., Xue, M., Gao, M., Yu, P., & Han, S. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00396-6 · Cited by 15 · see citing works

Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis

Shi, H., Zhang, W., Zhang, L., Zheng, Y., & Dong, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1265202 · Cited by 14 · see citing works

Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy

Zhou, L., Shao, L., Gao, S., Cui, C., Chi, Z., Sheng, X., Tang, B., Mao, L., Lian, B., Yan, X., et al. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac005 · Cited by 14 · see citing works

Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2

Li, W., Mei, W., Jiang, H., Wang, J., Li, X., Quan, L., Diao, Y., Ma, Y., Fan, S., Xie, Z., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2706-2 · Cited by 13 · see citing works

Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma

Yamamoto, Y., Matsuyama, H., Matsumoto, H., Sakano, S., Fuji, N., Oba, K., Yamamoto, M., Kamiryo, Y., Hiragino, T., Nagao, K., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz168 · Cited by 13 · see citing works

Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials

Bai, X. L., Dai, J., Li, C., Cui, C., Mao, L., Wei, X., Sheng, X., Chi, Z., Yan, X., Tang, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639085 · Cited by 12 · see citing works

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer

Que, Y., Wang, J., Zhu, J., Li, N., Huang, J., Lü, S., Sun, F., Zhang, L., Zhen, Z., Zhang, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647733 · Cited by 13 · see citing works

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Dani, K., Rich, J. M., Kumar, S. S., Cen, H., Duddalwar, V. A., & D'souza, A. (2023) · Cancers · doi:10.3390/cancers15204934 · Cited by 12 · see citing works

PD-1 Inhibitor Aggravate Irradiation-Induced Myocardial Fibrosis by Regulating TGF-β1/Smads Signaling Pathway via GSDMD-Mediated Pyroptosis

Wu, B., Zhao, S., Zhang, J., Liu, Y., Bai, J., Wang, G., Wang, Y., Jiang, H., Hu, Y., Ouyang, W., et al. (2024) · Inflammation · doi:10.1007/s10753-024-02056-9 · Cited by 12 · see citing works

Primary vaginal malignant melanoma successfully treated with combination therapy: A case report

Yin, P., Ma, X., Zhang, Y., Song, Y., Wang, Y., & Lü, Z. (2022) · Oncology Letters · doi:10.3892/ol.2022.13550 · Cited by 12 · see citing works

Immune checkpoint inhibitor‐based therapy for advanced acral and mucosal melanoma

Mori, T., Izumi, T., Doi, R., Kamimura, A., Takai, S., Teramoto, Y., & Nakamura, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14725 · Cited by 12 · see citing works

Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma

Zhao, L., Yang, Y., Ma, B., Li, W., Li, T., Han, L., Zhang, Y., Shang, Y., Lin, H., & Gao, Q. (2019) · Journal of Oncology · doi:10.1155/2019/6454989 · Cited by 12 · see citing works

Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma

Wu, Y., Wei, D., Ren, G., & Guo, W. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04090-2 · Cited by 11 · see citing works

Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives

Liu, Y., Deng, Y., Yang, C., & Naranmandura, H. (2024) · Bioengineering · doi:10.3390/bioengineering11111084 · Cited by 11 · see citing works

Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy

Grafanaki, K., Maniatis, A., Anastogianni, A., Bania, A., Pasmatzi, E., & Stathopoulos, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124193 · Cited by 12 · see citing works

Diagnostic and prognostic value of heat shock protein 90α in malignant melanoma

Zhang, T., Li, Q., Zhang, Y., Wang, Q., Wang, H., & Gu, K. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000716 · Cited by 11 · see citing works

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial

Chen, J., Li, C., Cao, Y., Zhu, L., Zhang, B., You, J., Hou, H., Wang, J., & Yuan, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-09866-w · Cited by 11 · see citing works

Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review

Nelson, B. E., Hong, A., & Jana, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705294 · Cited by 10 · see citing works

Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma

Mo, Z., Liu, J., Zhang, J., Deng, Y., Xu, M., & Jiang, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110973 · Cited by 9 · see citing works

Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)

Wei, A. Z., Chen, L. N., Orloff, M. M., Ariyan, C. E., Asgari, M. M., Barker, C. A., Buchbinder, E. I., Chandra, S., Couts, K. L., Frumovitz, M. M., et al. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13139 · Cited by 8 · see citing works

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype

SHENG, X. N., Huang, G., Fang, M., Li, K., Wu, D., Zhang, X., Chen, J., Zhu, D., Chen, Y., Li, H., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2025.5751 · Cited by 8 · see citing works

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

Day, D., Park, J., Coward, J. I. G., Markman, B., Lemech, C., Kuo, J. C.-Y., Prawira, A., Brown, M. P., Bishnoi, S. K., Kotasek, D., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02431-7 · Cited by 8 · see citing works

The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study

Chen, Y., Liu, Y., Feng, H., Liu, T., Zhang, J., Wang, J., Lu, J., Rossi, A., Riaño, I., Hu, P., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-378 · Cited by 8 · see citing works

Serum long non-coding RNA LOC553103 as non-specific diagnostic and prognostic biomarker for common types of human cancer

Pan, H., Sun, L., Wang, W., Qin, Z., Tang, L.-B., Gu, X., Zhang, J., & He, B. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.017 · Cited by 8 · see citing works

Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay

Liu, S., Yang, J., Yang, S., Tan, Q., Dai, L., Fan, G., Wu, D., Zhang, Z., Yao, J., Shi, Y., et al. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114515 · Cited by 8 · see citing works

Adoptive T-cell Immunotherapy: Perfecting Self-Defenses

Zur-Toledano, R., Adler, G., Shamalov, K., Tal, Y., Ankri, C., & Cohen, C. J. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_9 · Cited by 8 · see citing works

Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis

Huo, G., Liu, W., Zhang, S., & Chen, P. (2023) · Immunotherapy · doi:10.2217/imt-2022-0140 · Cited by 9 · see citing works

Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors

Wang, H., Liu, Y., Deng, L., Jiang, K., Yang, X., Wu, X., Guo, K., & Wang, F. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03032-3 · Cited by 8 · see citing works

Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy

Zhou, L., Yang, Y., Si, L., Chi, Z., Sheng, X., Lian, B., Wang, X., Tang, B., Mao, L., Yan, X., et al. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000809 · Cited by 8 · see citing works

Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes

Liu, D., Wang, X., Liu, X., & Li, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1689820 · Cited by 8 · see citing works

Programmed cell death protein 1 in cancer cells

Wei, C., Liu, M., & Zhang, W. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02155-6 · Cited by 7 · see citing works

MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients

Yu, J., Xu, L., Yan, J., Yu, J., Wu, X., Dai, J., Guo, J., & Kong, Y. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00619-2 · Cited by 7 · see citing works

Additional file 1: of Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Tang, B., Yan, X., Sheng, X., Si, L., Cui, C., Kong, Y., Lili, M., Lian, B., Bai, X., Wang, X., et al. (2019) · Figshare · doi:10.6084/m9.figshare.7587365

A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.

Chi, Z., Tang, B., Sheng, X., Si, L., Cui, C., Kong, Y., Li, D., Li, S. M., Yan, X., Mao, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3067 · Cited by 1 · see citing works

A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.

Chi, Z., Tang, B., Sheng, X., Si, L., Cui, C., Kong, Y., Chen, Y., Qin, S., Chen, J., Wu, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9539 · Cited by 16 · see citing works

Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.

Sheng, X., Chi, Z., Cui, C., Si, L., Tang, B., Yan, X., & Guo, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e16505 · Cited by 4 · see citing works

Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors

Fh, W., Ren, C., Zhang, Y., Yao, S., Feng, H., Wu, H., Song, H.-F., Zhang, R., Wei, X.-L., Xia, X.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.051 · Cited by 3 · see citing works